FDA Approves First Treatment For Rare Disease In Patients Who Receive Stem Cell Transplant From Blood Or Bone Marrow

FDA Approved

The U. S. Food and Drug Administration approved Defitelio (defibrotide sodium, Jazz Pharmaceuticals, Inc.) for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstructive syndrome, with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).

More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm493278.htm

© 2021 FLASCO | Premium Website Design by The HDG